Effects of C-Tactile-optimal Touch on Alcohol Craving and Relapse-Related Biomarkers in Alcohol Use Disorder
NCT07920601, Not applicable, Completed, Aalto University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of C-Tactile-optimal Touch on Alcohol Craving and Relapse-Related Biomarkers in Alcohol Use Disorder | ClinicalTrials.gov |
| NCT number | NCT07920601 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 21 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Aalto University | ClinicalTrials.gov |
| Conditions | Alcohol Use Disorder | ClinicalTrials.gov |
| Interventions | CT- optimal Robotic skin stimulation, Non-CT-optimal Robotic skin stimulation | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Heart rate variability (HRV) reactivity as a biomarker of stress and a predictor of susceptibility to relapse | Measurement taken during each participant's first study visit for approximately 32 minutes. | To assess autonomic functioning, Standard deviation of normal-to-normal intervals (SDNN) HRV (ms) is derived from blood volume pulse (BVP) measured with Empatica E4 wrist band device throughout Experiment 1. excluding a 15-minute relaxation at the end of the experimental session. | ClinicalTrials.gov |
| Primary | Self-reported Alcohol craving | The first and second study visits. Maximum 7 days in between the visits. | In the experiment performed during the first study visit a visual analog scale to assess self-reported subjective craving is shown before and after each cue exposure. The guestion "If alcohol was available to me right now..." is shown with a ten-point scale in which 1 = I would not want to drink it at all, 10 = I would not be able to resist drinking even if I tried. In the experiment at the second study visit a five-point visual analog scale for rating the alcohol craving is shown after each alcohol-related image in the cue reactivity task. In this on the queston is "How willing are you to drink the drink in the previous image…" 1 = I would not want to drink it at all, 5 = I would not be able to resist drinking even if I tried. | ClinicalTrials.gov |
| Primary | Salivary cortisol as a biomarker of stress and a predictor of susceptibility to relapse | First study visit. The time points of the saliva collection were the baseline, after the first 10 minutes of the treatment, after the visual stimuli, at the end of the treatment and after the 15-minute relaxation period. | To assess the salivary cortisol levels (ng/ml), saliva samples are collected 5 times during the Experiment 1. (total 15 samples per participant). The saliva is collected by placing a synthetic swab between the tongue and the cheek of the participants for minimum 2 min after which it was placed in a plastic tube and stored in -20 °C until the analysis. | ClinicalTrials.gov |
| Primary | Pupillary reactivity as a predictor of susceptibility to relapse | Second study visit (maximum 7 seven days after ensrollment). Recorded during a cue reactivity task test for approximately 5 minutes. | Pupillary reactivity measurements are conducted in the Aalto Behavioral Laboratory (ABL) using an EyeLink 1000 Plus eye-tracking system during the Experiment 2. Pupil size (mm) is recorded continuously throughout the cue-reactivity task at a sampling frequency of 500 Hz. Pupil size is recorded monocularly from the participant's dominant eye, as determined prior to the session. | ClinicalTrials.gov |
| Primary | Event related potentials (ERP's) of electroencephalography (EEG) as a biomarker for predicting a vulnerability to relapses | Second study visit (maximum 7 seven days after ensrollment. EEG will be recorded though out the cue reactivity task test for approximately 5 minute. | ERPs (microVolts) of EEG will be recorded using an BrainAmp amplifier and an ActiCap 32-channel electrode set during the cue reactivity task test (Experiment 2.) Focus will be on P3 amplitudes. Patients with AUD, as well as other substance use disorders, have larger P3 amplitudes elicited by substance-related than neutral stimuli which indicates that P3 amplitudes reflect the neural correlates of substance craving . In addition, the AUD patients with reduced P3 amplitudes to alcohol cues are less likely to relapse than those with larger P3 amplitudes. | ClinicalTrials.gov |
| Secondary | Number of patients experiensing adverse reactions (Safety and Tolerability) | 3 weeks from the enrollment (First and second study visits and a two-week follow-up) | Number of patients experiensing adverse reactions during the experimets and follow-up and numer of reported reactions | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 39608682 | RESULT | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Food Cue Reactivity Task | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)